Saltz LB, Clarke S, Díaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS, Rivera F, Couture F, Sirzén F, Cassidy J (2008) Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 26:2013–2019. https://doi.org/10.1200/JCO.2007.14.9930

Article  CAS  PubMed  Google Scholar 

Fuchs CS, Marshall J, Mitchell E, Wierzbicki R, Ganju V, Jeffery M, Schulz J, Richards D, Soufi-Mahjoubi R, Wang B, Barrueco J (2007) Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. J Clin Oncol 25:4779–4786. https://doi.org/10.1200/JCO.2007.11.3357

Article  CAS  PubMed  Google Scholar 

Douillard JY, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham D, Jassem J, Rivera F, Kocákova I, Ruff P, Błasińska-Morawiec M, Šmakal M, Canon JL, Rother M, Oliner KS, Wolf M, Gansert J (2010) Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 28:4697–4705. https://doi.org/10.1200/JCO.2009.27.4860

Article  CAS  PubMed  Google Scholar 

Peeters M, Price TJ, Cervantes A, Sobrero AF, Ducreux M, Hotko Y, André T, Chan E, Lordick F, Punt CJ, Strickland AH, Wilson G, Ciuleanu TE, Roman L, Van Cutsem E, Tzekova V, Collins S, Oliner KS, Rong A, Gansert J (2010) Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol 28:4706–4713. https://doi.org/10.1200/JCO.2009.27.6055

Article  CAS  PubMed  Google Scholar 

Coates A, Abraham S, Kaye SB, Sowerbutts T, Frewin C, Fox RM, Tattersall MH (1983) On the receiving end–patient perception of the side-effects of cancer chemotherapy. Eur J Cancer Clin Oncol 19:203–208. https://doi.org/10.1016/0277-5379(83)90418-2

Article  CAS  PubMed  Google Scholar 

de Boer-Dennert M, de Wit R, Schmitz PI, Djontono J, v Beurden V, Stoter G, Verweij J, (1997) Patient perceptions of the side-effects of chemotherapy: the influence of 5HT3 antagonists. Br J Cancer 76:1055–1061. https://doi.org/10.1038/bjc.1997.507

Article  PubMed  PubMed Central  Google Scholar 

Carelle N, Piotto E, Bellanger A, Germanaud J, Thuillier A, Khayat D (2002) Changing patient perceptions of the side effects of cancer chemotherapy. Cancer 95:155–163. https://doi.org/10.1002/cncr.10630

Article  PubMed  Google Scholar 

Nozawa K, Shimizu C, Kakimoto M, Mizota Y, Yamamoto S, Takahashi Y, Ito A, Izumi H, Fujiwara Y (2013) Quantitative assessment of appearance changes and related distress in cancer patients. Psychooncology 22:2140–2147. https://doi.org/10.1002/pon.3268

Article  PubMed  Google Scholar 

Tahara M, Shirao K, Boku N, Yamaguchi K, Komatsu Y, Inaba Y, Arai T, Mizunuma N, Satoh T, Takiuchi H, Nishina T, Sakata Y (2008) Multicenter Phase II study of cetuximab plus irinotecan in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin and fluoropyrimidines. Jpn J Clin Oncol 38:762–769. https://doi.org/10.1093/jjco/hyn102

Article  PubMed  Google Scholar 

Muro K, Yoshino T, Doi T, Shirao K, Takiuchi H, Hamamoto Y, Watanabe H, Yang BB, Asahi D (2009) A Phase 2 clinical trial of panitumumab monotherapy in Japanese patients with metastatic colorectal cancer. Jpn J Clin Oncol 39:321–326. https://doi.org/10.1093/jjco/hyp016

Article  PubMed  Google Scholar 

Lacouture ME, Mitchell EP, Piperdi B, Pillai MV, Shearer H, Iannotti N, Xu F, Yassine M (2010) Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-emptive Skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer. J Clin Oncol 28:1351–1357. https://doi.org/10.1200/JCO.2008.21.7828

Article  CAS  PubMed  Google Scholar 

Jonker DJ, O’Callaghan CJ, Karapetis CS, Zalcberg JR, Tu D, Au HJ, Berry SR, Krahn M, Price T, Simes RJ, Tebbutt NC, van Hazel G, Wierzbicki R, Langer C, Moore MJ (2007) Cetuximab for the treatment of colorectal cancer. N Engl J Med 357:2040–2048. https://doi.org/10.1056/NEJMoa071834

Article  CAS  PubMed  Google Scholar 

Van Cutsem E, Peeters M, Siena S, Humblet Y, Hendlisz A, Neyns B, Canon JL, Van Laethem JL, Maurel J, Richardson G, Wolf M, Amado RG (2007) Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 25:1658–1664. https://doi.org/10.1200/JCO.2006.08.1620

Article  CAS  PubMed  Google Scholar 

Stintzing S, Kapaun C, Laubender RP, Jung A, Neumann J, Modest DP, Giessen C, Moosmann N, Wollenberg A, Kirchner T, Heinemann V (2013) Prognostic value of cetuximab-related skin toxicity in metastatic colorectal cancer patients and its correlation with parameters of the epidermal growth factor receptor signal transduction pathway: results from a randomized trial of the German AIO CRC study group. Int J Cancer 132:236–245. https://doi.org/10.1002/ijc.27654

Article  CAS  PubMed  Google Scholar 

Takahashi H, Asaka J, Tairabune T, Ujiie H, Matsuura Y, Nihei S, Kimura T, Chiba T, Kudo K (2021) Analysis of risk factors for skin disorders caused by anti-epidermal growth factor receptor antibody drugs and examination of methods for their avoidance. J Clin Pharm Ther 46:1404–1411. https://doi.org/10.1111/jcpt.13475

Article  CAS  PubMed  Google Scholar 

Takahashi H, Yaegashi Y, Saito Y, Nihei S, Tairabune T, Ujiie H, Asaka J, Kudo K (2022) Effect of risk factors for acneiform rash induced by anti-epidermal growth factor receptor antibody drugs on survival: a retrospective observational study. J Pharm Health Care Sci 8:22. https://doi.org/10.1186/s40780-022-00253-y

Article  PubMed  PubMed Central  Google Scholar 

Kikuchi K, Nozawa K, Yamazaki N, Nakai Y, Higashiyama A, Asano M, Fujiwara Y, Kanda S, Ohe Y, Takashima A, Boku N, Inoue A, Takahashi M, Mori T, Taguchi O, Inoue Y, Mizutani H (2019) Instrumental evaluation sensitively detects subclinical skin changes by the epidermal growth factor receptor inhibitors and risk factors for severe acneiform eruption. J Dermatol 46:18–25. https://doi.org/10.1111/1346-8138.14691

Article  CAS  PubMed  Google Scholar 

Chandra F, Sandiono D, Sugiri U, Suwarsa O, Gunawan H (2017) Cutaneous side effects and transepidermal water loss to gefitinib: a study of 11 patients. Dermatol Ther (Heidelb) 7:133–141. https://doi.org/10.1007/s13555-016-0163-0

Article  PubMed  Google Scholar 

Levin J, Maibach H (2005) The correlation between transepidermal water loss and percutaneous absorption: an overview. J Control Release 103:291–299. https://doi.org/10.1016/j.jconrel.2004.11.035

Article  CAS  PubMed  Google Scholar 

Löffler H, Aramaki JU, Effendy I (2002) The influence of body mass index on skin susceptibility to sodium lauryl sulphate. Skin Res Technol 8:19–22. https://doi.org/10.1046/j.0909-752x

Article  PubMed  Google Scholar 

Nakahara T, Moroi Y, Takayama K, Itoh E, Kido-Nakahara M, Nakanishi Y, Furue M (2015) Changes in sebum levels and the development of acneiform rash in patients with non-small cell lung cancer after treatment with EGFR inhibitors. Onco Targets Ther 8:259–263. https://doi.org/10.2147/OTT.S76860

Article  PubMed  PubMed Central  Google Scholar